TY - JOUR

T1 - The dynamic effects of preoperative intravenous iron in anaemic patients undergoing surgery for colorectal cancer

AU - Bojesen, Rasmus Dahlin

AU - Eriksen, Jens Ravn

AU - Vogelsang, Rasmus Peuliche

AU - Grube, Camilla

AU - Forman, Julie Lyng

AU - Gogenür, Ismail

N1 - This article is protected by copyright. All rights reserved.

PY - 2021

Y1 - 2021

N2 - AIM: The aim of this study was to describe the dynamic changes in blood work following individual adjusted dosage of intravenously administered iron(III)isomaltoside in a 4-week period prior to surgery in patients with colorectal cancer.METHODS: This was a single-center, observational cohort study with prospectively collected data, including patients with colorectal cancer receiving preoperative treatment with iron(III)isomaltoside. Blood samples were taken at baseline, one week, two weeks, and four weeks after initial treatment. Sixty-two patients were included in the study.RESULTS: Sixty-two patients were included for final analysis. The mean increase in haemoglobin was 0.77 g/dL (95% CI: 0.52-1.03, p<0.0001) at week 1, 1.5 g/dL (95% CI: 1.21-1.80, p<0.0001) at week 2, and 2.13 g/dL (95% CI: 1.71-2.55, p<0.0001) at week four. Patients with severe anaemia (<9.02 g/dL) showed the largest increase in haemoglobin during the treatment course (2.92 g/dL (95% CI: 2.27-3.58 g/dL, p<0.0001). Patients with mild anaemia (>10.31 g/dL) did not show a significant increase (0.66 g/dL (95% CI: -0.29-1.61, p=0.17) The mean of transferrin saturation after four weeks was 8% (95% CI: 6%-10%, p<0.0001).CONCLUSIONS: After intravenously administered iron, patients with severe anaemia had the most substantial increase in haemoglobin, and the increase was largest after four weeks. Patients with mild anemia did not have an increase in haemoglobin during the treatment course. The vast majority of patients still had iron deficiency at surgery four weeks after the initial treatment.

AB - AIM: The aim of this study was to describe the dynamic changes in blood work following individual adjusted dosage of intravenously administered iron(III)isomaltoside in a 4-week period prior to surgery in patients with colorectal cancer.METHODS: This was a single-center, observational cohort study with prospectively collected data, including patients with colorectal cancer receiving preoperative treatment with iron(III)isomaltoside. Blood samples were taken at baseline, one week, two weeks, and four weeks after initial treatment. Sixty-two patients were included in the study.RESULTS: Sixty-two patients were included for final analysis. The mean increase in haemoglobin was 0.77 g/dL (95% CI: 0.52-1.03, p<0.0001) at week 1, 1.5 g/dL (95% CI: 1.21-1.80, p<0.0001) at week 2, and 2.13 g/dL (95% CI: 1.71-2.55, p<0.0001) at week four. Patients with severe anaemia (<9.02 g/dL) showed the largest increase in haemoglobin during the treatment course (2.92 g/dL (95% CI: 2.27-3.58 g/dL, p<0.0001). Patients with mild anaemia (>10.31 g/dL) did not show a significant increase (0.66 g/dL (95% CI: -0.29-1.61, p=0.17) The mean of transferrin saturation after four weeks was 8% (95% CI: 6%-10%, p<0.0001).CONCLUSIONS: After intravenously administered iron, patients with severe anaemia had the most substantial increase in haemoglobin, and the increase was largest after four weeks. Patients with mild anemia did not have an increase in haemoglobin during the treatment course. The vast majority of patients still had iron deficiency at surgery four weeks after the initial treatment.

U2 - 10.1111/codi.15789

DO - 10.1111/codi.15789

M3 - Journal article

C2 - 34166572

VL - 23

SP - 2550

EP - 2558

JO - Colorectal Disease

JF - Colorectal Disease

SN - 1462-8910

IS - 10

ER -